A cohort compassionate-use program with cabazitaxel plus prednisone for patients with metastatic castration-resistant prostate cancer: Interim results.

172 Background: In the Phase III TROPIC trial (NCT00417079), cabazitaxel/prednisone (CbzP) improved overall survival compared with mitoxantrone/prednisone in patients (pts) with mCRPC who had progressed on or after prior docetaxel (D) (HR 0.70; P < 0.0001). The survival benefit observed supported the establishment of 2 programs (based on local regulations): a compassionate use (CUP) and an early access program (EAP) (NCT01254279). Methods: The aims of both programs are to provide drug to pts with mCRPC who may benefit from CbzP prior to commercial availability, and further evaluate CbzP safety profile. Total enrollment for both programs is targeted to be 1,600 pts from 250 centers in Europe, Asia, Latin America and Canada. Eligible pts will receive CbzP (25 mg/m2 Q3W plus oral prednisone 10 mg daily) until disease progression, death, unacceptable toxicity or physician/pt decision. Results: Baseline characteristics and safety data are available for the first 399 pts. Median age was 68 yrs (range 43–89); 90...